ArticleJACC. Basic to translational science2017
Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law.
Article in JACC. Basic to translational science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
- Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology.Advanced healthcare materials · 2026Review
- Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in human engineered cardiac connective tissue.iScience · 2025Article
- Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.European journal of heart failure · 2025Review
- Disease foci of pharmaceutical research and development as reflected in applications for International Nonproprietary Names, 1953-2022.Bulletin of the World Health Organization · 2025Article
- 3D Bioprinting for Engineered Tissue Constructs and Patient-Specific Models: Current Progress and Prospects in Clinical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- (3D) Bioprinting-Next Dimension of the Pharmaceutical Sector.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Molecular origin and biological effects of exercise mimetics.Journal of exercise science and fitness · 2024Review
- Computational integration and meta-analysis of abandoned cardio-(vascular/renal/metabolic) therapeutics discontinued during clinical trials from 2011 to 2022.Frontiers in cardiovascular medicine · 2023Article
- Unraveling the relationships between alpha- and beta-adrenergic modulation and the risk of heart failure.Frontiers in cardiovascular medicine · 2023Article
- A New Versatile Platform for Assessment of Improved Cardiac Performance in Human-Engineered Heart Tissues.Journal of personalized medicine · 2022Article
- Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury.PLoS pathogens · 2020Article
- Permeability of Epithelial/Endothelial Barriers in Transwells and Microfluidic Bilayer Devices.Micromachines · 2019Article
- Phase II Trials in Drug Development and Adaptive Trial Design.JACC. Basic to translational science · 2019Article
- Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience.JACC. Basic to translational science · 2019Article
- Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".JACC. Basic to translational science · 2018Article
- The Rising Cost of Developing Cardiovascular Therapies and Reproducibility in Translational Research: Do Not Blame It (All) on the Bench.JACC. Basic to translational science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eroom's law (Moore's law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades. Therapeutics for cardiovascular diseases (CVD) appear to have been particularly sensitive to these trends. Thirty-three percent fewer CVD therapeutics were approved between 2000 and 2009 compared to the previous decade, and the number of CVD drugs starting all clinical trial stages declined in both absolute and relative numbers between 1990 and 2012. In the last 5 years, drugs to treat CVD disease comprised just 6% of all new drug launches. This review discusses the decline in CVD therapeutics, the reasons behind it, and ways in which this trend is being or might be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.